![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EU Expands CE Mark for Dako Companion Diagnostics
EU Expands CE Mark for Dako Companion Diagnostics
Agilent Technologies has receive an expanded CE mark for its Dako PD-L1 IHC 22C3 pharmDx which can now be used to determine PD-L1 expression status to inform the first-line treatment of metastatic non-small cell lung cancer patients with Keytruda.
The intended use allows PD-L1 IHC 22C3 pharmDx to detect PD-L1 expression in both untreated and previously treated metastatic patients.
Upcoming Events
-
21Oct